Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Zymeworks BC Inc. (ZYME)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/04/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results |
| 11/03/2021 |
8-K
| Quarterly results |
| 08/04/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 02/24/2021 |
8-K
| Quarterly results |
| 11/03/2020 |
8-K
| Quarterly results |
| 08/05/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 03/02/2020 |
8-K
| Quarterly results |
| 11/05/2019 |
8-K
| Quarterly results |
| 08/02/2019 |
8-K
| Quarterly results |
| 05/02/2019 |
8-K
| Quarterly results|
Docs:
|
"Zymeworks Reports 2019 First Quarter Financial Results Vancouver, Canada - Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the first quarter ended March 31, 2019. “We are pleased to have advanced both of our lead assets to the next stages of clinical development; recently commencing a Phase 2 study for ZW25 and starting enrollment in the Phase 1 clinical trial for our antibody-drug conjugate, ZW49,” said Ali Tehrani, Ph.D., Zymeworks' President & CEO. “Accordingly, we have also expanded our leadership team, adding experienced executives with critical competencies needed to facilitate the development and approval of our clinical-stage assets. We believe we are now well-positioned to deliver on our ambi..." |
|
| 03/06/2019 |
8-K
| Quarterly results|
Docs:
|
"Zymeworks Reports 2018 Year-End Financial Results Vancouver, Canada - Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the year ended December 31, 2018. “Over the past year, we have made significant progress advancing our own pipeline while our partners continued developing their assets using our technology,” said Ali Tehrani, Ph.D., Zymeworks' President & CEO. “Our lead program, ZW25, continued to generate impressive clinical data and our second product candidate, ZW49, recently began a Phase 1 clinical trial. We also established our seventh and eighth pharmaceutical partnerships while our long-term partner, Eli Lilly, advanced two of their Azymetric™ bispecifics into the clinic.” Dr. Tehrani continue..." |
|
| 11/06/2018 |
8-K
| Quarterly results|
Docs:
|
"Zymeworks Reports Financial Results for the Third Quarter of 2018 Vancouver, Canada - Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018. “We continue to expand our business with our seventh pharmaceutical partner, LEO Pharma, recently entering into a strategic collaboration with Zymeworks,” said Ali Tehrani, Ph.D., Zymeworks' President & CEO. “Importantly, this deal represents the evolving structure of our partnerships to include collaborations that provide potential assets for pipeline expansion in new disease areas, as well as significant royalty participation.” Dr. Tehrani continued, “In addition, results from the Phase 1study for ZW25 will be presented in a..." |
|
| 08/01/2018 |
8-K
| Quarterly results|
Docs:
|
"Zymeworks Reports Financial Results for the Second Quarter of 2018 Vancouver, Canada - Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2018. “This was a pivotal quarter for Zymeworks highlighted by the oral presentation of ZW25 clinical data at the ASCO annual meeting,” said Ali Tehrani, Ph.D., Zymeworks' President & CEO. “With the completion of our subsequent financing, we are well capitalized to accelerate the clinical development of ZW25 into registrational studies.” Dr. Tehrani continued, “We also have a number of important near-term catalysts including providing the refined regulatory strategy for ZW25, supported by a clinical update; filing an Investigational Ne..." |
|
| 05/01/2018 |
8-K
| Quarterly results|
Docs:
|
"Zymeworks Reports 2018 First Quarter Financial Results Vancouver, Canada - Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the quarter ended March 31, 2018. “Over the last few months we have added to our clinical and business momentum,” said Ali Tehrani, Ph.D., Zymeworks' President & CEO. “In addition to the milestones highlighted below, we continue to be encouraged by the clinical progress of our lead candidate, ZW25, and are honored that the updated data was selected for an oral presentation at the upcoming American Society of Clinical Oncology annual meeting next month. First Quarter 2018 Business Highlights and Recent Developments • Added New Clinical Sites for ZW25 in Canada and the United States..." |
|
| 03/14/2018 |
8-K
| Quarterly results|
Docs:
|
"Zymeworks Reports 2017 Year-End Financial Results Vancouver, Canada - Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the year ended December 31, 2017. “2017 was marked by a number of key corporate successes,” said Ali Tehrani, Ph.D., Zymeworks' President & CEO. “We continued to generate promising clinical results for ZW25, added a sixth global pharmaceutical partner, and saw important progress in our partners' programs as they advanced compounds utilizing our technology towards the clinic.” 2017 Business Highlights and Recent Developments • Expanded Clinical Dataset for ZW25 The Company reported results from the dose-escalation portion of its ongoing Phase 1 clinical trial, showing encouraging tolera...",
"Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition" |
|
|
|